Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study
There are limited data on the efficacy of adjuvant therapy in ampullary cancer. The aim of this study was to determine whether adjuvant therapy was associated with improved survival for patients with ampullary cancer.
From the National Cancer Database, we identified ampullary cancer patients who underwent resection between 2004 and 2013. We performed 1:1 propensity score matching, comparing patients who had postoperative observation to patients who received adjuvant chemotherapy (ACT) or adjuvant chemoradiotherapy (ACRT).
We identified 4190 patients who fit our inclusion criteria; 63% had postoperative observation, 21% received ACT, and 16% underwent ACRT. In the matched cohorts, the use of ACT was associated with improved overall survival (HR = 0.82, 95% CI = 0.71 to 0.95). The median overall survival was 47.2 months for the ACT group and 35.5 months for the observation group. In a separate matched analysis, ACRT was also associated with improved survival (HR = 0.84, 95% CI = 0.72 to 0.98) as compared to observation. The median overall survival was 38.1 months for the ACRT group and 31.0 months for the observation group. The benefit was more pronounced in high-risk patients, such as ones with higher T and N categories.
In this retrospective study, the use of adjuvant therapy in ampullary cancer was associated with significantly improved overall survival. The benefit of adjuvant therapy for this disease should be confirmed in a more rigorous fashion via randomized controlled trials.
KeywordsAdjuvant therapy Ampullary cancer Ampullary carcinoma Chemotherapy Chemoradiation
The authors would like to thank Dave Primm for his help in editing this manuscript and Helen Mayo from the UT Southwestern Health Sciences Digital Library and Learning Center for the assistance with literature searches.
Ibrahim Nassour, Linda Hynan, Alana Christie, and Sam Wang: study design, data analysis and interpretation, writing initial draft, revising and approving the final draft
Rebecca Minter, Adam Yopp, Michael Choti, John Mansour, and Matthew Porembka: data interpretation, revising and approving the final draft
Source of Funding
The National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001105.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 8.National Cancer Data Base. https://www.facs.org/quality%20programs/cancer/ncdb. Accessed Jul 2016.
- 9.Parson LS: Performing a 1: N case-control match on propensity score: Proceedings of the 29th Annual SAS Users Group International Conference. 2004Google Scholar
- 13.Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308:147–156.CrossRefPubMedGoogle Scholar
- 14.Neoptolemos JP, Moore MJ, Cox TF, et al. Ampullary cancer ESPAC-3 (v2) trial: a multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater J Clin Oncol. 2016;29:LBA4006.CrossRefGoogle Scholar
- 15.Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82; discussion 782-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized Study. J Clin Oncol.2017;35 (suppl; abstr 4006).Google Scholar
- 25.Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315:1844–1853.CrossRefPubMedGoogle Scholar